This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the potential of Iovance's tumor infiltrating lymphocyte (TIL) therapy, lifileucel, in advanced unresectable or metastatic melanoma

Ticker(s): IOVA

Who's the expert?

Institution: Dana Farber Cancer Institute

  • Clinical Director of the Melanoma Disease Center, Director of Clinical Sciences for the Center for Immuno-Oncology, and Senior Physician at Dana Farber Cancer Institute
  • Treats 50 patients per month with advanced unresectable or metastatic melanoma
  • Clinical Interest and expertise in immunotherapy and melanoma and is the PI for several Phase 1 studies in melanoma.

Interview Goal
On this call we will discuss the potential hurdles Iovance Biotherapeutics faces for FDA final approval of  tumor infiltrating lymphocyte (TIL) therapy, lifileucel, and its commercial opportunity in treating patients with advanced unresectable or metastatic melanoma who have received anti–PD-1/L1 therapy and targeted therapy.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.